Abstract
Background and ImportanceAbemaciclib in combination with endocrine therapy (ET) has recently been authorised for adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2) negative and luminal early...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have